Trial Profile

Phase III confirmatory trial of adjuvant girentuximab in patients with clear cell renal cell carcinoma stratified using the CAIX biomarker

Status: Planning

Phase of Trial: Phase III

Latest Information Update: 27 Nov 2017

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Girentuximab (Primary)
Indications Renal cancer
Focus Biomarker; Registrational; Therapeutic Use
Sponsors Heidelberg Pharma AG

Most Recent Events

19 Oct 2017 According to a Heidelberg Pharma AG media release, WILEX AG changed its name to Heidelberg Pharma AG.
13 Jun 2013 Study title is not official; assumed registrational.
13 Jun 2013 New trial record

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com